TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05516316
Drug: EP395
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsule for oral use
Study: NCT05516316
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule for oral use
Study: NCT06111209
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: weekly by intramuscular injection
Study: NCT06044857
Drug: 68-Ga PSMA11
Approvals — FDA: no, EMA: no, PMDA: no
Description: Will be injected/assessed in line with its FDA label.
Study: NCT06139211
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabin will be administered orally twice daily from day 1 to 14 every 21 day cycle.
Study: NCT05417750
Drug: TIL therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: A tumor sample is resected from each participant and cultured ex vivo to expand the population of autologous tumor infiltrating lymphocytes injection (GC101 TIL). After lymphodepletion, patients are infused GC101 TIL followed sintilimab.
Study: NCT06040190
Drug: topical placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individuals will be instructed to dissolve half a tablet of placebo medication and hold the saliva near the painful oral sites without swallowing, for 3 minutes and then spit. Tablets will contain magnesium silicate, with the same color and flavor as the test medications. Researchers will provide a total of 32 tablets for each participant.
Study: NCT05035524
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05800015
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion, Q3W
Study: NCT06139211
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil will be administered intravenously (IV) on days 1 and 15 every 28 day cycle.
Study: NCT06139211
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Leucovorin will be administered intravenously (IV) on days 1 and 15 every 28 day cycle.
Study: NCT06088888
Drug: TGRX-678
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants are given TGRX-678 tablets orally, once daily, at one of the dose levels as pre-determined for the dose escalation sequence or expansion cohorts.
Study: NCT05756166
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT06217042
Drug: HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin 85 mg/m² D1 over 2 hours, followed by HR070803 60 mg/m² D1 over 90 minutes, after the Folinic acid infusion is started. Folinic acid 400 mg/m² D1, IV infusion over 1 hours. 5-FU 2400 mg/m² D1 IV continuous infusion over 46 hours.~These drugs are given once every 2 weeks, 12 cycles, 24 weeks.
Study: NCT06217042
Drug: gemcitabine; capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1000mg/m² is given as an i.v. infusion over 30 minutes, administered on day 1, 8 and 15 out of 28 days. Capecitabine 1660mg/m²/day in two divided doses administered orally for 21 days followed by 7 days'rest .
Study: NCT05123482
Drug: AZD8205
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD8205 is an antibody drug conjugate that has the potential to treat a wide variety of solid tumors including but not limited to breast cancer, Biliary Tract Cancer, ovarian, endometrial cancers and squamous non-small cell lung cancers.
Study: NCT06313255
Drug: PegIFNα2b+probiotics
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients receive both PegIFNα2b and probiotics therapy
Study: NCT06313255
Drug: Nucleoside analog
Normalized name: Nucleoside analog
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients receive nucleoside analog therapy
Study: NCT05794581
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo as SC Injection
Study: NCT06313255
Drug: Nucleoside analog+probiotics
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients receive both nucleoside analog and probiotics therapy
Study: NCT05231798
Drug: [18F]-FEOBV Radiotracer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be administered an \[18F\]-fluoroethoxybenzovesamicol (FEOBV) radiotracer for diagnostic imaging purposes (PET scan).
Study: NCT05942365
Drug: ZSP1273
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug Warfarin oral Drug midazolam oral
Study: NCT05051436
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered for 14 weeks after baseline procedures.
Study: NCT04955236
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1µg/kg/hr. of intravenous fentanyl infusion will be administered. A syringe filled with 20 ml of normal saline will be prepared and 3 ml of normal saline will be injected at the same points of the partial scalp block previously described
Study: NCT06145269
Drug: New oral anticoagulant (rivaroxaban) and Marevan (warfarin)
Normalized name: New Day Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: comparison between 2 drug, (rivaroxaban) and Marevan (warfarin)
Study: NCT05019430
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: The pharmacodynamic effects of placebo will be determined.
Study: NCT06126510
Drug: Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VG161:1.0×10\^8PFU/day, intratumoral injection administration for 3 consecutive days, 28 days as a cycle
Study: NCT04028713
Drug: Dose reduction
Normalized name: Rebetron Combination Package for Rebetol Dose Reduction, Intron A 6,000,000 UNT/ML Multi-Dose Vial / 42 Rebetol Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab dosing frequency will be lowered in patients who have supratherapeutic serum trough levels of adalimumab.
Study: NCT05432206
Drug: Cannabis Sativa Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabis Sativa oil standardized: 11 mg THC/g and 22 mg CBD/g.
Study: NCT05432206
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemp virgin seed oil
Study: NCT05700006
Drug: Aromatase inhibitor
Normalized name: Aromatase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care anastrozole, exemestane, or letrozole
Study: NCT06535308
Drug: BnH-015B 5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Korean / 3 on BnH-015B, 1 on placebo
Study: NCT06535308
Drug: BnH-015B 40 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caucasian / 6 on BnH-015B, 2 on placebo
Study: NCT06535308
Drug: BnH-015B 160 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Korean / 6 on BnH-015B, 2 on placebo
Study: NCT06535308
Drug: BnH-015B 40 mg (MAD)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Korean / 6 on BnH-015B, 2 on placebo
Study: NCT06535308
Drug: BnH-015B 80 mg (MAD)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Korean / 6 on BnH-015B, 2 on placebo
Study: NCT06535308
Drug: BnH-015B 80 mg (Part II)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Korean / 9 subjects
Study: NCT06535308
Drug: BnH-015B Placebo (Part II)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Korean / 6 subjects
Study: NCT05571059
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching oral placebo
Study: NCT06039540
Drug: Spironolactone Tablets
Normalized name: Spironolactone Tablets
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2-4mg/kg, bid
Study: NCT05514275
Drug: Endostatin and Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients received radiotherapy Combined With Endostatin(37.5mg/m2, continuous intravenous infusion for 120h, D-7, D8, D22, D36) and Capecitabine( 650 mg/m2 bid, orally, d1-21, every 3 weeks as a cycle for 17 cycles)
Study: NCT04576975
Drug: Normal Saline 0.9%
Normalized name: BD Posiflush Normal Saline 0.9% Prefilled Syringe Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: compare the use of ketamine versus dexmedetomidine when used as perioperative infusion in obese patients undergoing laparoscopic bariatric surgery regarding their analgesic efficacy as well as any side effects or drawbacks (PONV and effects on consciousness) that might associate with their use.
Study: NCT05660356
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pfizer provided placebo
Study: NCT05270057
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose level -2=10 mg/m\^2; dose level -1; dose level -1=10 mg/m\^2; dose level 1=10 mg/m\^2; dose level 2=12 mg/m\^2; dose level 3=14.4 mg/m\^17.3 mg/m\^2; dose level 4=17.3 mg/m\^2; dose level 5=20.7 mg/m\^2; dose level 6=24.8 mg/m\^2; dose level 7=29.8 mg/m\^2.
Study: NCT05270057
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dose level -2=480 mg/m\^2; dose -1=600 mg/m\^2; dose level 1=750 mg/m\^2; level 2=900 mg/m\^2; level 3=1080 mg/m\^2; level 4=1296 mg/m\^2; level 5=1555 mg/m\^2; level 6=1866 mg/m\^2; level 7=2239 mg/m\^2.
Study: NCT04987294
Drug: ALLN-346
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALLN-346 (Engineered Urate Oxidase) is an orally administered, novel urate oxidase; provided as capsules for oral administration
Study: NCT04987294
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo capsules are similar in weight and appearance to the ALLN-346 capsules
Study: NCT05486598
Drug: AL8326 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequence A group: on the 1st day, take a single dose of AL8326 tablets on an empty stomach. On the 15th day, take a single dose of AL8326 tablets after meals.~Sequence B group: on the 1st day after meal, take a single dose of AL8326 tablets; on the 15th day, take a single dose of AL8326 tablets on an empty stomach.
Study: NCT06699680
Drug: PRX019
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT06699680
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05239468
Drug: Obeticholic Acid placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet of obeticholic acid placebo tablet once daily
Study: NCT05655819
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose powder dissolved in 8 ounces of water or juice prior to drinking, taken orally three times per day. Looks exactly like the study drug, but it contains no active ingredient.
Study: NCT06349798
Drug: NaCl 0.9%
Normalized name: DEXTROSE 5%/NACL 0.9% INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 ml of saline, during a 30 min infusion, before end of procedure, followed by a bolus of placebo every 4 hours for 24 hours (6 injections in all) + continuous infusion of placebo (2 mL/h of physiological saline)
Study: NCT05421741
Drug: Antibiotic coated intramedullary Nail
Normalized name: Fungi-Nail
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic coated intramedullary nail:~A mixture of 40gm bag of acrylic cement, antibiotic powder (Vancomycin 2gm) and 560mg gentamicin liquid. The intramedullary is coated with the mixture using a cement gun tube.
Study: NCT04892017
Drug: DCC-3116
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Tablet Formulation
Study: NCT05552625
Drug: TADIOS
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TADIOS is a combination extract which composed of three herbs, and each herbal medicine has been traditionally used as a food or a herbal medicine treating various respiratory diseases in Asia
Study: NCT05552625
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of the following Lactose hydrate, Microcrystalline cellulose, Colloidal silicone dioxide, Povidone, Croscarmellose sodium, Magnesium stearate, Tabshield(79O245)
Study: NCT05263206
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection solution SC
Study: NCT03863288
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo intranasal spray liquid administration
Study: NCT06456567
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection
Study: NCT05717361
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In the Remifentanil group, patients will be administered in a total volume of 20 mL, 2 mcg/kg of fentanyl. As maintenance, they will be receiving 1 mL/10kg/h of a remifentanil solution
Study: NCT05758246
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment
Study: NCT05291091
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is administered orally once per day
Study: NCT05693935
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Period 1, 2 monthly injections (Period 1 only)
Study: NCT05722522
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participants will receive placebo s.c. at randomization (Baseline visit), Week 1, 2, 3, 4, 8, and 12
Study: NCT05439629
Drug: BAT5906 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.0 mg/eye/time, 50 μl, intravitreal injection
Study: NCT05243823
Drug: Vagifem®
Approvals — FDA: no, EMA: no, PMDA: no
Description: According to local clinical practice - independent of inclusion in this study
Study: NCT05243823
Drug: Non-Vagifem® LDVE, Estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: According to local clinical practice - independent of inclusion in this study
Study: NCT06247462
Drug: Ibuprofen 600 mg
Normalized name: ibuprofen 600 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 mg of ibuprofen was ingested 12- and 1-hours prior to exercise.
Study: NCT05366335
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: The invesitigators give patients normal saline as a placebo infusion during their colonoscopy examination for a single time in the control group.
Study: NCT04939051
Drug: Placebo Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT05366335
Drug: Basic treatment
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: The invesitigators give patients general treatment and drug treatment including oral Live Combined Bifidobacterium and Lactobacillus tablets as basic treatment.
Study: NCT04163328
Drug: HydroEye®
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is an omega-3 fatty acids supplement.
Study: NCT05208814
Drug: TPN171H single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg TPN171H taken once
Study: NCT06338995
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT05972681
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine (1:200,000) injected to the vaginal laceration site.
Study: NCT05873192
Drug: ADT
Normalized name: Radtue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by PO
Study: NCT05873192
Drug: Luprolide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO or given INJ
Study: NCT05132153
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: will be given by nebuliztion
Study: NCT06159621
Drug: CD 40 Agonist - LVGN 7409
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of one dose of LVGN 7409 - 1mg/kg
Study: NCT06780865
Drug: Placebo-controlled group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants are treated with corresponding placebo
Study: NCT02988297
Drug: RNS60
Normalized name: Ronasin 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized RNS60 will be administered by daily inhalation for 24 weeks.
Study: NCT02988297
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized Placebo will be administered by daily inhalation for 24 weeks.
Study: NCT05183061
Drug: Ehedrine Norepineprine
Approvals — FDA: no, EMA: no, PMDA: no
Description: No interventions required considering that this was a retrospective study.
Study: NCT06223711
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant chemotherapy consists of further two cycles platinum/etoposide q3w (summarized cycle 3-4).
Study: NCT05045768
Drug: (Gelsectan, Devintec Sagl)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients included in the study will receive for 28 days a capsule containing Xyloglucan, Pea Protein and Grape Seed Extract and a prebiotic Xylo-oligosaccharide (Gelsectan, Devintec sagl) twice daily.
Study: NCT05723198
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT06792162
Drug: Carilizumab and Apatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: After every 2 cycles of meparticipants. Apatinib was discontinued for one cycle and an additional course of Carilizumab was administered in preparation for surgery. The time between the last dose and surgery was 3-6 weeks, with a maximum of 6 weeks. Both surgical and non-surgical participants will continue to receive treatment with the original regimen of Carilizumab combined with Apatinib after surgery until disease progression, recurrence, or death, for a maximum of 2 years.
Study: NCT06048627
Drug: Amine/zinc lactate/fluoride system
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amine/zinc lactate/fluoride system (250 ppm F), meridol®, Colgate-Palmolive
Study: NCT05414422
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concentrate for solution for infusion
Study: NCT06435936
Drug: Single Ascending Dose of Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single ascending dose
Study: NCT06261502
Drug: CBD Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will start with oral CBD dose of 5 mg/kg/day for two weeks and then increase to 10 mg/kg/day.
Study: NCT06261502
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a dose of a placebo composed of the inactive ingredients of CBD of the same volume as the CBD Oral Solution.
Study: NCT05676203
Drug: Standard ADT (androgen deprivation therapy)
Approvals — FDA: no, EMA: no, PMDA: no
Description: as prescribed by the treating physician.
Study: NCT05931575
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 ml Quinine dihydrochloride solution (from Quinina Labesfal) in screw flask supplemented with 30 ml Glucose 40% solution from miniplasco directly before use
Study: NCT04968990
Drug: DD-4A Chemotherapy Regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive standard of care chemotherapy based on diagnosis and stage.
Study: NCT05512403
Drug: PET/CT with 18F-DOPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: A 18F-FDOPA PET exam is then performed (acquisition of 30 minutes in List Mode format) according to the French guidelines for PET neuro-oncological indications (Verger et al. Med Nuc, 2020, (5)).~Patient preparation and acquisition:~* 4 hours of fasting~* No carbidopa premedication~* 2 MBq / kg of 18F-FDOPA~* Dynamic acquisition in List Mode format for 30 min starting simultaneously with the patient's injection~* Low dose scanner for attenuation correction
Study: NCT06701903
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablet, taken once daily, sublingual administration
Study: NCT06294912
Drug: MK-7602
Normalized name: vitamin MK 7
DrugBank: Vitamin K7 (DB15664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules to be administered orally.
Study: NCT06784622
Drug: Treatment as usual
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Well-Root PT is clinically used in many areas such as pulp capping, perforation and resorption repair, root tip filling and apexification. As Well-Root PT is available in pre-mixed capsule form, it can provide a consistent and adequate consistency and clinical convenience. Well-Root PT can be applied directly into the oral cavity by placing the capsule in a syringe. In addition, Well-Root PT has a shorter setting time than MTA.Despite these advantages, there is no study in the literature on the effect of Well-Root PT on postoperative pain and tooth vitality after pulpotomy in mature permanent molars
Study: NCT06776679
Drug: [14C]-BGB-16673
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally as suspension in lipid vehicle
Study: NCT05686408
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will take 1 tablet orally once daily for 6 weeks.
Study: NCT06423352
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered by SC injection
Study: NCT04686539
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Oil
Study: NCT05320640
Drug: Immune checkpoint inhibitors（anti-PD1/PD-L1/CTLA4 antibodies）
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune checkpoint inhibitors (ICIs) have emerged as effective therapies for many cancers by promoting the reactivation and restoring function of T cells.
Study: NCT05022303
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be administered orally four times a day (QID) to the standard of care for MIS-C.
Study: NCT05466422
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo as an IV infusion on Days 1, 29, and 57
Study: NCT05379179
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: This study will compare patient-reported pain scores after receiving either ketamine or fentanyl for the treatment of acute pain due to a rattlesnake bite.
Study: NCT06317285
Drug: GSK3915393
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3915393 will be administered.
Study: NCT06317285
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered.
Study: NCT05434156
Drug: ELE-101 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: ELE-101 placebo matching solution for intravenous infusion
Study: NCT05493111
Drug: 0.003% AR-15512 ophthalmic solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered via topical ocular instillation
Study: NCT01970124
Drug: KPS-0373, Low dose
Approvals — FDA: no, EMA: no, PMDA: no